Skip to main content
. 2014 Sep 11;122(1):107–118. doi: 10.1111/1471-0528.13070

Figure 3.

Figure 3

Anti-HPV–16 (A) and anti-HPV–18 (B) antibody levels in initially seronegative women aged 15–55 years (ATP cohort for immunogenicity at year 6). Key: [15–25], women aged 15–25 years at the time of first vaccine dose; [26–45], women aged 26–45 years at the time of first vaccine dose; [46–55], women aged 46–55 years at the time of first vaccine dose; GMT, geometric mean titre; Nat-inf, natural infection. GMTs of women who were (A) HPV–16 or (B) HPV–18 DNA-negative and seropositive at baseline (i.e. who had cleared a natural infection). GMTs were (A) 29.8 EU/ml and (B) 22.6 EU/ml.35,36 Plateau: GMTs of women aged 15–25 years at months 45–50 after the first vaccine dose (total vaccinated cohort). GMTs were (A) 397.8 EU/ml and (B) 297.3 EU/ml.33 The error bars represent 95% confidence intervals.